Target Validation and DNA Damage Response Group
Professor Tutt’s group interests involve the discovery of novel therapies and biomarkers in BRCA1/BRCA2-associated cancers and ER/HER2-negative/basal-like breast cancers – including the identification of new drug targets and therapy combination strategies.